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Identity 
Other names: CD44R; CDW44; CDw44; CSPG8; 
ECMR-III; Epican; HCELL; HUTCH-I; IN; LHR; 
MC56; MDU2; MDU3; MGC10468; MIC4; MUTCH-
I; PGP-1; PGP-I; Pgp1 




Consists of 20 exons spanning a length of 60 kb. The
first five and the last five exons are constant; Exons 1-5 
and Exons 15-19 encode the N-terminal (extracellular) 
and C-terminal (extracellular, transmembrane, and 
cytoplasmic) domains respectively, and share 
homologous domains among all the CD44 family 
members. The ten exons (Exons 5a-14) located 
between these regions are, however, subjected to 




742 amino acids. 
Apart from alternative splicing, further diversity arises 
from post-translational modifications with N-  
and O-glycosylation and glycosaminoglycanation by 
heparan sulphate or chondroitin sulphate to generate 
multiple CD44 isoforms (at least 20 are known) of 
different molecular sizes (85-230 kDa). 
Other post-translational modifications include cleavage 
by specific proteinases (possibly matrix 
metalloproteinases) in the extracellular matrix (ECM), 
(de)phosphorylation (activation of protein kinase C 
results in dephosphorylation of Ser-706, a constitutive 
phosphorylation site, and the phospho-rylation of Ser-
672). 
N-terminal segment interacts with hyaluronan and other 
glycosaminoglycans, collagen, laminin and fibronectin. 
C-terminal segment interacts with ANK, ERM proteins 
(VIL2, RDX and MSN), and NF2. 
Expression 
Standard CD44 (CD44s), which is the smallest CD44 
molecule (85-95kDa), lacks the entire variable region. 
It is a single-chain molecule containing several 
domains: a distal extracellular domain (N-terminal 
containing the ligand-binding sites), a membrane-
proximal region, a transmem-brane domain, and a 
cytoplasmic domain. High interspecies homology 
among CD44 isoforms is exhibited through these basic 
domains (with the exception of the membrane-proximal 
region). As CD44s is mostly expressed on cells of 
lympho-haematopoietic origin, it is also known as 
haematopoietic CD44 (CD44H). 
 
 
CD44 gene is located at chromosome 11 on the short arm (p13). 
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(A) CD44 gene consists of 20 exons. Exons 1-5 and Exons 15-19 encode homologous N-terminal and C-terminal domains respectively. 
Exons 5a-14 (v1 to v10) generate CD44 variants through alternative splicing. (B) CD44s consists of the homologous domains but lacks 
the entire variable region. (C) CD44v6 is one example of a CD44 variant isoform which contains the variant Exon 6. 
 
 
CD44s consists of the basic domains (and structure) whereas CD44v has an additional longer stem, which contains the variant exon(s). 
 
The CD44 variant isoforms (CD44v) are identified by 
the presence of variant exon(s). These CD44 variant 
isoforms can be upregulated by T lympho-cytes and 
other leukocytes after immunological activation. Their 
expression patterns are tissue specific: CD44 lacking 
v2-v10 is the most common form on haematopoietic 
cells while larger CD44 splice variants dominate on 
certain normal and neoplastic epithelia, activated 
lymphocytes and malignant lymphomas. A CD44 
isoform consisting of the last three exon products of the 
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variable region (CD44V8-10) is preferentially 
expressed on epi-thelial cells, hence it is also called 
epithelial CD44 or CD44E. In contrast, CD44V3-10, 
the longest CD44 isoform that expresses eight exons of 
the variable region, has been observed in keratinocytes. 
Localisation 
Membrane; single-pass type I membrane protein. 
Function 
CD44 is a multifunctional receptor which plays a role 
in cell adhesion (cell-cell and cell-ECM interactions), 
cell traffic, lymph node homing, presentation of 
chemokines and growth factors, transmission of growth 
signals and signals mediating haematopoiesis and 
apoptosis. 
Ligand-binding: The principal ligand of CD44 is HA, 
an important component of the ECM. CD44 is involved 
in the uptake and intracellular degradation of HA. 
Other CD44 ligands include ECM components such as 
collagen, fibronectin, laminin, and chondroitin 
sulphate. ECM-unrelated ligands include mucosal 
addressin, serglycin, osteopontin, and the class II 
invariant chain. 
CD44 expression in tumours: High levels of expression 
of CD44 have been observed in numerous cancer cell 
types. Some tumours, such as gliomas, express CD44s 
only. In contrast, other cancers, including 
gastrointestinal carcinoma, bladder cancer, uterine 
cervical cancer, breast carcinoma and non-Hodgkin's 
lymphomas, express CD44 variants at higher levels. In 
addition, results from animal studies showed that 
introduction of CD44s- or CD44v-specific antibodies 
impeded CD44-ligand interaction and led to inhibition 
of local tumour growth and distant metastasis. These 
suggest that CD44 may confer a growth advantage on 
some tumours and could thus be a target for cancer 
therapy. In addition, CD44v may be a useful diagnostic 




Breast cancer is the most common cancer among 
women globally, with more than 1.1 million women 
diagnosed each year. It is also the main cause of dath 
from cancer in females worldwide. 
Breast cancer can be of the non-invasive type in which 
the cancer cells are confined within the mammary ducts 
or lobes. The non invasive type can be further divided 
into ductal carcinoma in situ and lobular in situ 
subtypes. In invasive breast carcinoma, cancer cells 
invade into surrounding tissues and metastasise. 
Invasive breast cancer constitutes up 70 to 80% of 
cases of breast cancer, and includes invasive ductal 




Depends on tumour size and grade, presence of 
oestrogen and progesterone receptors, occurrence of 
nodal/regional metastasis, peritoneal vascular invasion 
and rate of tumour growth. 
CD44+/CD24- breast cancer stem cells have been 
linked to tumourigenesis and may be associated with
poor patient survival rate. 
The various CD44 isoforms may play a part in breast 
cancer prognosis. The loss of CD44s is found to be 
associated with an increased risk of metastasis. 
CD44v3 and CD44v6 are positively correlated to breast 
cancer tumourigenesis and metastasis, and poor patient 
prognosis. CD44v7-8 has also been shown to be 
positively associated with poor overall patient survival 
rate. 
Cytogenetics 
Chr11 is involved in the chromosomal abnormal-lities 
in breast cancer. Comparative genomic hybridisation 
(CGH) profiles of Chr11 in breast cancer shows lack of 
changes on the short arm (11p) and frequent gains or 
losses on the long arm (11q). The distribution of loss of 
heterozygosity (LOH) regions on Chr11 that were 
consistently observed includes 11p15.5, 11q13 and 
11q23. 
Oncogenesis 
Different CD44 isoforms are associated with various 
stages of breast cancer progression. CD44s is 
downregulated in malignant breast cancer tissues 
compared against benign breast tissues. Nevertheless, 
CD44s has been reported to be essential for breast 
cancer invasion and metastasis to the liver. CD44 with
variant exon 4 is upregulated in breast cancer and plays 
a role in cancer cell migration across endothelial 
monolayers. Soluble CD44v6 is elevated in cancerous 
tissues and positively correlated with larger tumour size 
and lymph node metastasis. Invasive cribiform breast 
tumours have been observed to have higher expression 
levels of both CD44v3 and v6, as well as reduced 
expression of CD44v4. In relation to hormonal 
receptors, a positive correlation has been reported 
between CD44v6 and breast carcinoma tissues with 
higher expression levels of estrogen and progesterone 
receptors. CD44s and CD44v9 expression levels are 
positively correlated with breast cancer tissues with 
elevated expression of estrogen receptors. 
Prostate cancer 
Disease 
Prostate cancer is currently ranked the fifth most 
common cancer worldwide. It is usually diagnosed in 
older men aged 50 years old and above. 
Prostate cancer pathological stages range from Stage I, 
in which the cancer is limited to the prostate gland d 
the cancer cannot be felt or seen, to Stage IV, in which 
cancer cells have metastasised to other parts of the 
body such as the bladder, rectum, lymph nodes or 
bones. 
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Prognosis 
Dependent on cancer staging, Gleason score, PSA 
level, patient's age and health, and the presence of 
recurrence. 
CD44s and CD44v6 may have prognostic values in 
determining overall patient survival rate. Loss of 
CD44s expression has been found to aid in predicting 
cancer recurrence whereas reduced expression of 
CD44v6 has been positively correlated with tumour 
progression and reduced patient survival rate. 
Cytogenetics 
Through cytogenetic methods such as CGH and  
fluorescence in situ hybridization (FISH), Chr11p13 
was reported to be deleted in sporadic prostate tumours. 
In addition, CD44 was found to be inactivated in both 
primary and metastatic prostate cancers. 
Oncogenesis 
Compared against benign prostate tissues, significat 
downregulation of CD44s occurs in prostate cancer. 
The promoter region of CD44 consisting of a CpG 
island can undergo hypermethylation at the CpG 
dinucleotides, leading to transcriptional repression and 
downregulation of CD44s. On the other hand, CD44 
variant isoforms such as CD44v6 and CD44v7-10 are 
overexpressed in prostate cancer. Increased CD44v6 
expression is positively linked with prostate tumour 
stage and metastasis. Upregulation of CD44v7-10 
occurs in both primary and metastatic prostate 
carcinoma. The variant isoforms make cancer cells bind
preferentially to fibronectin rather than to hyaluronan. 
In addition, CD44 variants can activate matrix 
metalloproteinase-9, an important step in prostate 
cancer cell migration. 
Cervical cancer 
Disease 
There are two major histopathological subtypes of 
cervical cancer. Most cervical cancers are squamous 
cell carcinoma where the tumour develops from 
squamous cells covering the surface of the exocervix. 
Adenocarcinoma, originating from mucus-producing 
cells of the endocervix, accounts for another 10-20% of 
cases. 
Prognosis 
Depends on cancer stage, presence of metastasis, and 
the presence of recurrence. 
A study showed that patients with early stage cervial 
cancer without involvement of pelvic lymph nodes but
express CD44v6 expression have poor overall survival. 
Furthermore, patients with CD44v6 expression in 
metastatic tumours in the pelvic lymph nodes were 
found, more frequently, to have involvement of at least 






From an LOH study, it was observed that there were 
frequent losses of the short arm of Chr11 as well as 
fewer than expected normal Chr11. 
Oncogenesis 
Exons v6 and v7-8 are promising indicators for 
identifying patients with increased risk of cervical 
cancer at an earlier stage. Both have prognostic values, 
as they are associated with poorer survival rate in 
patients diagnosed with Stage III cervical cancer. 
Colon cancer 
Disease 
Colon cancer is the third most commonly diagnosed 
cancer worldwide and is the fourth most frequent cause 
of death form cancer globally. Most colon cancers are 
adenocarcinomas. 
Prognosis 
Depends on the tumour growth stage, presence of 
metastasis. 
CD44v3, v5, v6, and v8-10 are possible prognostic 
indicators in colon cancer. 
Cytogenetics 
Gain of Chr11 has been observed in a human colon 
adenocarcinoma cell line HT29, and may play a part in 
tumourigenesis and metastasis. 
Oncogenesis 
CD44v isoforms are overexpressed in malignant colon 
cancer cells. Increased CD44v6 and CD44v8-10 
expression were found to enhance HA binding, 
tumourigenicity and distant metastasis. Co-expres-sion 
of CD44v3 and heparanase is also associated with 
metastasis. CD44v5 can serve as an early marker for 
colon cancer when detected on small dysplastic polyps. 
Elevated CD44 with Exon v6 is associated with tumour 




The most common form of rectal cancer is 
adenocarcinoma, which develops from the mucosa. The 
malignant tumour can metastasise to lymph nodes and 
other parts of the body. 
Prognosis 
CD44v6 is a promising prognostic factor which may 
help in predicting overall survival rate. 
Oncogenesis 




Brain cancers can generally be classified into prima y  
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brain tumours and secondary brain tumours. Primary 
brain tumours occur when the tumour begins in the 
brain tissue and the most common type are gliomas. 
Secondary brain tumours occur when cancer cells 
spread from another part of the body to the brain. It is
more common than primary brain tumours. 
Prognosis 
Depends on the type of brain tumour, size and locati n 
of the tumour, grade and stage of the cancer. 
Cytogenetics 
From trypsin-Giemsa staining and multicolour FISH, 
chromosomal aberrations were found on Chr11p in 
medulloblastoma, a subtype of brain cancer which 
occurs mainly in children. 
Oncogenesis 
In primary brain cancers, CD44 isoforms composed of 
single-variant Exons v3, v4, v6 or v9 were observed to 
be weakly expressed. In metastatic  
brain tumours, CD44 isoforms including those with 
multiple variant exons were overexpressed. However, it 
was observed that brain cancer cells that metastasise to 
the spine were negative for CD44v. Other studies 
showed that CD44v5/v6 was homogenously expressed 
in brain cancer tissues whereas CD44v7-10 expression 
was upregulated in a fraction of brain tumour cells. 
Pancreatic cancer 
Disease 
About 95% of pancreatic cancer cases begin in the 
pancreatic. A rare type of pancreatic cancer is 
pancreatic islet cell cancer where the tumour occurs in 
the cells that make insulin and other hormones. 
Prognosis 
Depends on cancer stage, whether the cancer is 
surgically removable, presence of recurrence, and 
patient's general health. 
CD44v2 and v6 may be useful markers of poor 
prognosis as their expressions were correlated with 
decreased overall patient survival. 
Cytogenetics 
Gain of Chr11q has been observed in CGH. 
Oncogenesis 
CD44s, CD44v3, CD44v4 and CD44v6 are expressed 
at moderate levels in pancreatic tumour cell lines. 
CD44v7 is expressed at low levels, whereas CD44v7/8 
and CD44v10 are expressed in very low amounts. 
Additionally, CD44v2 is observed only in tumour cells 
and is associated with vessel invasion. 
Lung cancer 
Disease 
Lung cancer is the leading cause of cancer death 
worldwide. The two main types of lung cancer are 
small cell lung carcinoma (SCLC) and non-small cell 
lung carcinoma (NSCLC). NSCLC is further 
subdivided into squamous cell lung carcinoma which 
originates near central bronchi, adenocarci-noma 
(originating from peripheral lung tissues) and large cell 
lung carcinoma (found near the surface or outer edges 
of the lung). 
Prognosis 
Depends on cancer stage, type of lung cancer, presenc  
of metastasis, presence of recurrence, and general 
health of the patient. 
In NSCLC, high expression of CD44v6 was associated 
with poor prognosis.  
In adenocarcinoma and large cell lung carcinoma, 
downregulation of CD44s, CD44v3 and v6 were\linked 
to poor patient survival rate. 
Cytogenetics 
In SCLC, Chr11 has a frequent breakpoint at 11p11-12 
and is often a recipient of translocated material on the 
short arm. Other translocations and deletions have also 
been observed on the long arm. 
Oncogenesis 
CD44v6 expression is positively linked to metastasi in 
NSCLC. However, the variant 6 isoform and CD44v3 
are negatively correlated with invasion in lung 
adenocarcinoma. Additionally, both CD44v3 and v6 
mRNAs are not always translated into functional 




Liver cancer is ranked among the top ten cancer types 
worldwide. Hepatocellular carcinoma is the most 
common type of liver cancer. Other forms include 
intrahepatic cholangiocarcinoma and fibro-lamellar 
carcinoma. 
Prognosis 
In poorly differentiated hepatocellular carcinoma, 
CD44 isoforms such as CD44s, v5, v6, v7-8 and v10 
are upregulated and associated with poorer overall 
patient survival rate. 
Oncogenesis 
Upregulated CD44v6 expression is coupled with the 
presence of vascular invasion. 
Stomach cancer 
Disease 
The most common form of gastric cancer is 
adenocarcinoma, where the tumour arises from the 
gastric glands. The malignant cells can invade through 
the stomach wall and spread to nearby organs and 
lymph nodes. 
Prognosis 
CD44v6 and sCD44v6 are positively correlated with 
tumour progression in the diffuse type of gastric cancer 
and lower patient survival rate. 
Cytogenetics 
Chr11 is involved in chromosomal abnormalities in 
gastric carcinoma and correlated with poor prognosis. It 
was observed in a CGH study that the 11p11.2-14 
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region, containing the CD44 gene at Chr11p13, was 
highly amplified. 
Oncogenesis 
Serum concentration of soluble CD44 variant 6 isoform 
is correlated with the depth of invasion and presence of 
metastatic tumour cells as well as cancer stage in 
patients with diffuse type gastric cancer. Thus, 
sCD44v6 may be a valuable prognostic indicator. 
The ratio of CD44E to CD44H expression in gastric 
cancer tissues was also observed to be significantly  
 
higher than in non-cancerous tissues. Patients with 
elevated E/H ratio have reduced survival rates. 
CD44v3 showed no association with cancer spread or 
patient survival. 
Non-Hodgkin Lymphoma (NHL) 
Disease 
NHL is the most common cancer of the lymphatic  
system with at least 61 subtypes. It is generally divided 
into B-cell lymphoma and T-cell lymphoma. NHL may 
occur in lymph nodes, specialised lymphatic organs 
(such as the spleen) or lymphatic tissues (such as t ose 
in the stomach), and is able to spread via the lymphatic 
vessels and blood stream. 
Prognosis 
The International Prognostic Index (IPI) is a useful 
method in determining survival outcome of patients 
with fast-growing lymphomas. The index consists of 
five factors: the patient's age, lymphoma stage, 
presence of metastasis, patient's performance status, 
and serum level of lactate dehydrogenase. 
Expressions of serum soluble CD44 at diagnosis as 
well as CD44 with Exon variant 6 are correlated with 
lower patient survival rate. 
Oncogenesis 
CD44 with variant Exons 6-10 are elevated in NHL. In 
vivo studies have indicated that CD44 containing 
directly-spliced Exon 10 is more highly associated with 
local tumour development and distant metastasis 
compared against larger Exon 10-containing variants 
(for example, CD44ex10-14 and CD44ex7-14) and 
CD44H. 
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